v3.26.1
License Agreements - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 12 Months Ended 15 Months Ended
Dec. 02, 2025
USD ($)
Nov. 05, 2025
USD ($)
Sep. 26, 2025
USD ($)
Apr. 28, 2025
USD ($)
Mar. 18, 2025
USD ($)
Feb. 28, 2026
USD ($)
Jan. 31, 2026
USD ($)
Oct. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2027
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Dec. 31, 2026
Mar. 31, 2026
employee
vote
Dec. 31, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
Mar. 26, 2026
shares
Asset Acquisition [Line Items]                                      
Deferred revenue, current                 $ 3,117     $ 3,117   $ 3,117     $ 4,156 $ 3,117  
Research and development [1]                 19,391 $ 12,081   37,294 $ 22,708            
Purchase of research and development license                       (8,000) 0            
Prepaid expenses and other current assets                 7,413     7,413   7,413     $ 5,463 7,413  
Paragon Option Agreements | Parascent Warrant                                      
Asset Acquisition [Line Items]                                      
Warrants, exercisable (in shares) | shares                                 402,731   34,566
License Agreement Terms | Paragon Option Agreements                                      
Asset Acquisition [Line Items]                                      
Number of employees overseeing and coordinating the project | employee                               2      
Paragon Therapeutics | Paragon Option Agreements                                      
Asset Acquisition [Line Items]                                      
Accounts payable and other current liabilities                 0     0   0     $ 100 $ 0  
Percent of outstanding shares                                 1.00%    
Paragon Therapeutics | Paragon Option Agreements | Forecast                                      
Asset Acquisition [Line Items]                                      
Percent of outstanding shares                             1.00%        
Paragon Therapeutics | License Agreement Terms | Paragon Option Agreements                                      
Asset Acquisition [Line Items]                                      
Number of employees overseeing and coordinating the project | employee                               2      
Number of votes | vote                               1      
Option agreement termination period, maximum contractual period                                   30 days  
Research and development                 0 $ 5,019   2,500 $ 13,033            
Paragon Therapeutics | License Agreement Terms | CR-001 | Paragon Option Agreements                                      
Asset Acquisition [Line Items]                                      
Non-refundable milestone payments         $ 22,000                            
Milestone payment       $ 3,000   $ 2,500                          
Restriction period                                   5 years  
Percent reduction to royalty payment due to invalid patent                                   30.00%  
Termination period due to breach of contract                                   60 days  
Sublicense agreement period                                   30 days  
Paragon Therapeutics | License Agreement Terms | CR-002 | Paragon Option Agreements                                      
Asset Acquisition [Line Items]                                      
Non-refundable milestone payments     $ 46,000                                
Milestone payment   $ 5,000           $ 5,000                      
Percent reduction to royalty payment due to invalid patent                                   30.00%  
Termination period due to breach of contract                                   60 days  
Sublicense agreement period                                   30 days  
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement                                      
Asset Acquisition [Line Items]                                      
Deferred revenue $ 20,000               20,000     20,000   20,000       $ 20,000  
Consideration transfer, period 30 days                                    
Development milestone payments $ 30,000                         30,000          
Contract with customer, liability                 15,000     15,000   15,000       15,000  
Contract with customer, refund liability                 5,000     5,000   5,000       5,000  
Deferred revenue, current                 3,100     3,100   3,100     $ 4,200 3,100  
Kelun-Biotech | License Agreement Terms | CR-001 | Collaborative Arrangement | License                                      
Asset Acquisition [Line Items]                                      
Contract with customer, liability                                 $ 10,800    
Contract with customer, liability, revenue recognized                 0     1,000              
Kelun-Biotech | License Agreement Terms | CR-001 | Forecast | Collaborative Arrangement                                      
Asset Acquisition [Line Items]                                      
Combination study approval payment                     $ 5,000                
Kelun-Biotech | License Agreement Terms | SKB105                                      
Asset Acquisition [Line Items]                                      
Consideration transferred 80,000                         80,000          
Development milestone payment 345,000                                    
Sale based milestone payment $ 902,500                                    
Mid-single digits to low-double digits royalty payment, period 18 months                                    
Low-single digits to low-double digits royalty payment, period 24 months                                    
Research and development                 0     0              
Purchase of research and development license             $ (8,000)                        
Prepaid expenses and other current assets                 $ 1,800     $ 1,800   $ 1,800       $ 1,800  
[1] Includes related party amount of $0 and $2,923 for the three and six months ended June 30, 2026 and $6,292 and $15,069 for the three and six months ended June 30, 2025, respectively.